Aurinia Pharmaceuticals Inc.AUPH
ASignal's systematic analysis rates AUPH as Bullish.
Reflects the latest available analysis · analyzed Aug 21, 2026
The case on AUPH
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong free cash flow of $147.82M
- High gross margin at 77.88%
- Excellent return on equity at 66.12%
- Low debt-to-equity ratio of 0.10x
- Current price near upper Bollinger Band, indicating momentum
- MACD histogram expanding above signal line, confirming bullish trend
- RSI at 68.12, approaching overbought territory
- Current price close to upper Bollinger Band, raising reversal risk
- Forward P/E of 15.61x implies higher valuation than current P/E of 7.30x
- No Reddit mentions, suggesting limited retail interest or potential data gap
See the full verdict on AUPH
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes AUPH
Most investors never get a second opinion, let alone several. ASignal runs AUPH past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.